Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a Bradykinin B2 receptor antagonist presented as a subcutaneous injection solution for subcutaneous use. It treats hereditary angioedema associated with C1‑inhibitor deficiency in patients requiring acute attack management.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema, a bradykinin‑mediated disorder.

Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during acute attacks, reducing duration and severity of symptoms.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or pruritus. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe angioedema: swelling of face, lips, or airway. - Hypotension: marked drop in blood pressure. - Thrombocytopenia: reduced platelet count. - Severe injection‑site necrosis: tissue damage at the site.

Before using Icatibant, consider the following safety measures.

Pregnancy: consult a healthcare professional; safety data are limited. Breastfeeding: discuss risks and benefits with a physician. Renal impairment: monitor closely as clearance may be affected. Concurrent bradykinin‑modulating therapy: avoid overlapping treatments. Allergy history: assess for prior hypersensitivity to peptide drugs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema. - Neprilysin inhibitors: elevate bradykinin, potentially reducing Icatibant efficacy. - Estrogen‑containing therapies: can exacerbate hereditary angioedema attacks.

Moderate Interactions (Monitor Closely): - Other B2‑receptor antagonists: additive pharmacodynamic effects. - Antihistamines: may mask early signs of hypersensitivity. - Corticosteroids: monitor for overlapping immunomodulatory effects. - Diuretics: watch for blood pressure fluctuations. - NSAIDs: potential for increased vascular permeability.